Vector Development for Cell and Gene Therapy Summit 2022

Vector Development for Cell and Gene Therapy Summit

Developing Scalable, Robust, GMP-Compliant Viral And Non-Viral Vector Manufacturing Processes For Optimized Cell And Gene Therapies

DOWNLOAD 2022 AGENDA
BOSTON, USA
24-25 August, 2022

“I thought it was well organized, a nice size for networking and discussion, and the quality of the presentations was high”

James Tasker, Ziopharm Oncology (Onco Cell Therapy Summit USA 2021 attendee)

Why Attend

The massive success of cell and gene therapies in recent years has made the need for effective, large scale vector engineering greater than ever. Though R&D efforts focussed on reducing immunogenicity and toxicity whilst improving redosing ability and durability are showing promise, companies are still striving to optimise these technologies and develop next-generation targeted, persistent and tolerable cell and gene therapies.

The Vector Development for Cell and Gene Therapy Summit is North America’s only event focused exclusively on addressing challenges in vector improvement for both ex vivo and in vivo approaches. Bringing together key industry leaders and covering a range of topics including capsid optimisation using AAV vectors, process optimisation using lentiviral and adenoviral vectors, innovative non-viral delivery options and the importance of vector serotype for improved durability, it’s a key opportunity to gain the actionable insights you’ll need to optimise your manufacturing process and improve tissue-specific targeting and safety profiles for your pipeline.

WHO WILL BE THERE

Network with industry experts from:

  • Senior-level leaders from biotech and big pharma
  • Internationally-renowned academic experts
  • Innovative vector development technology companies
  • Service & technology providers – CROs, CDMOs, delivery technology companies and more

Previous Cell Therapy series attendees include:

Get The Agenda

What to Expect:

  • Two dedicated tracks focused on in vivo and ex vivo vector optimization (talks from REGENXBIO, Spark Therapeutics, Umoja Biopharma), developing more efficient producer cell lines (talks from Vedere Bio, Ultragenyx, Sanofi) and process development improvements (talks from Pfizer, LogicBio, Bristol Myers Squibb).
  • Specific talks and discussion on how to efficiently meet the requirements in bringing drugs to market (Sangamo Therapeutics, Ring Therapeutics).
  • Exploration of the most effective vector serotypes to produce more durable gene expression (talks from SparingVision, MIT, Codiak Biosciences, Versatope Therapeutics).
  • Discussing the cutting-edge methods to reduce timelines for cell and gene therapy drug development (talks from University of Pennsylvania, Biogen).
  • Developing novel vectors to reduce immunogenicity, allowing for effective redosing (talks from SmartImmune, Genethon, UC Berkeley).

Get the agenda

OUR INDUSTRY-LEADING SPEAKERS

 

Abhishek Chatterjee

Professor
Boston College

Abhishek Chatterjee

Professor
Boston College

Abhishek Chatterjee

Professor
Boston College
 

Alex Ward

Director, Vector Production and Development
Sangamo Therapeutics

Alex Ward

Director, Vector Production and Development
Sangamo Therapeutics

Alex Ward

Director, Vector Production and Development
Sangamo Therapeutics
 

Christopher Locher

CEO
Versatope Therapeutics

Christopher Locher

CEO
Versatope Therapeutics

Christopher Locher

CEO
Versatope Therapeutics
 

David Schaffer

Professor
UC Berkeley

David Schaffer

Professor
UC Berkeley

David Schaffer

Professor
UC Berkeley
 

Elad Firnberg

Senior Scientist
REGENXBIO

Elad Firnberg

Senior Scientist
REGENXBIO

Elad Firnberg

Senior Scientist
REGENXBIO
 

Floris Engelhardt

Co-Founder
Kano Therapeutics

Floris Engelhardt

Co-Founder
Kano Therapeutics

Floris Engelhardt

Co-Founder
Kano Therapeutics
 

Georgios Katsikis

Postdoctoral Associate
MIT

Georgios ‘Yorgos’ Katsikis is a postdoctoral associate at MIT. He did his PhD in Mechanical Engineering at Stanford. After his PhD he worked at Carbon, a start-up company in Silicon Valley. He is currently at MIT, researching on nanotechnologies for characterization of viral vectors. For his research, he led a collaboration between three departments at MIT and Biomarin Pharmaceutical. He is interested in biotechnology, microfluidics, biophysics and rapid prototyping.

 

Georgios Katsikis

Postdoctoral Associate
MIT

Georgios Katsikis

Postdoctoral Associate
MIT

Georgios ‘Yorgos’ Katsikis is a postdoctoral associate at MIT. He did his PhD in Mechanical Engineering at Stanford. After his PhD he worked at Carbon, a start-up company in Silicon Valley. He is currently at MIT, researching on nanotechnologies for characterization of viral vectors. For his research, he led a collaboration between three departments at MIT and Biomarin Pharmaceutical. He is interested in biotechnology, microfluidics, biophysics and rapid prototyping.

 

 

Giuseppe Ronzitti

Group Leader
Genethon

Giuseppe Ronzitti

Group Leader
Genethon

Giuseppe Ronzitti

Group Leader
Genethon
 

Hesong Han

Senior Postdoctoral Student
UC Berkeley

Hesong Han

Senior Postdoctoral Student
UC Berkeley

Hesong Han

Senior Postdoctoral Student
UC Berkeley
 

James Richardson

Senior Director, Analytical Development
Interius Biosciences

James Richardson

Senior Director, Analytical Development
Interius Biosciences

James Richardson

Senior Director, Analytical Development
Interius Biosciences
 

James Voss

Institute Investigator
Scripps Research

James Voss

Institute Investigator
Scripps Research

James Voss

Institute Investigator
Scripps Research
 

Jing Liao

Director of Vector Operations
LogicBio

Jing Liao

Director of Vector Operations
LogicBio

Jing Liao

Director of Vector Operations
LogicBio
 

Joseph Gold

VP Technical Operations
Catamaran Bio

Joseph Gold

VP Technical Operations
Catamaran Bio

Joseph Gold

VP Technical Operations
Catamaran Bio
 

Li Ou

Vice President
Stealth Mode Biotech

Li Ou

Vice President
Stealth Mode Biotech

Li Ou

Vice President
Stealth Mode Biotech
 

Marina Cavazzana

Cofounder and Acting CMO
SmartImmune

Marina Cavazzana

Cofounder and Acting CMO
SmartImmune

Marina Cavazzana

Cofounder and Acting CMO
SmartImmune
 

Matthew Fuller

Senior Director, Vector Platform Research
Ultragenyx

Matthew Fuller

Senior Director, Vector Platform Research
Ultragenyx

Matthew Fuller

Senior Director, Vector Platform Research
Ultragenyx
 

Matt Stebbins

Principal Scientist
Bristol-Myers Squibb

Matt Stebbins

Principal Scientist
Bristol-Myers Squibb

Matt Stebbins

Principal Scientist
Bristol-Myers Squibb
 

Mauricio Umana

Senior Director Regulatory Affairs CMC
Ring Therapeutics

Mauricio Umana

Senior Director Regulatory Affairs CMC
Ring Therapeutics

Mauricio Umana

Senior Director Regulatory Affairs CMC
Ring Therapeutics
 

Michael Doherty

Scientist II
Codiak Biosciences

Michael Doherty

Scientist II
Codiak Biosciences

Michael Doherty

Scientist II
Codiak Biosciences
 

Pedro Moura

Head of Upstream Process Development
Spark Therapeutics

Pedro Moura

Head of Upstream Process Development
Spark Therapeutics

Pedro Moura

Head of Upstream Process Development
Spark Therapeutics
 

Rajani Shelke

Senior Scientist
Pfizer

Rajani Shelke

Senior Scientist
Pfizer

Rajani Shelke

Senior Scientist
Pfizer
 

Rajiv Gangurde

Chief Technology Officer
SparingVision

Rajiv Gangurde

Chief Technology Officer
SparingVision

Rajiv Gangurde

Chief Technology Officer
SparingVision
 

Richard Harbottle

Researcher
DKFZ Heidelberg

Richard Harbottle

Researcher
DKFZ Heidelberg

Richard Harbottle

Researcher
DKFZ Heidelberg
 

Ryan Crisman

Co-Founder and CTO
Umoja Biopharma

Ryan Crisman

Co-Founder and CTO
Umoja Biopharma

Ryan Crisman

Co-Founder and CTO
Umoja Biopharma
 

Saba Ghassemi

Research Assistant Professor
University of Pennsylvania Medicine

Saba Ghassemi

Research Assistant Professor
University of Pennsylvania Medicine

Saba Ghassemi

Research Assistant Professor
University of Pennsylvania Medicine
 

Sandro Marosevic

Assistant Professor
Purdue University

Sandro Marosevic

Assistant Professor
Purdue University

Sandro Marosevic

Assistant Professor
Purdue University
 

Saurabh Sen

Associate Director, Cell Line Development
Sanofi

Saurabh Sen

Associate Director, Cell Line Development
Sanofi

Saurabh Sen

Associate Director, Cell Line Development
Sanofi
 

Sunandan Saha

Principal Scientist
Obisidian Therapeutics

Sunandan Saha

Principal Scientist
Obisidian Therapeutics

Sunandan Saha

Principal Scientist
Obisidian Therapeutics
 

Xiaozhi Ren

Director, Cell Line and Process Development
Vedere Bio

Xiaozhi Ren

Director, Cell Line and Process Development
Vedere Bio

Xiaozhi Ren

Director, Cell Line and Process Development
Vedere Bio
 

Zsuzsanna Izsvak

Professor
Max Delbruck Center for Molecular Medicine

Zsuzsanna Izsvak

Professor
Max Delbruck Center for Molecular Medicine

Zsuzsanna Izsvak

Professor
Max Delbruck Center for Molecular Medicine

2022 partners

GMP Partner

Event Partner

Media Partners

Partner with us

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertise on the main stage to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact Ryan Sanderson, Commercial Partnerships Director at [email protected] or register your interest here.

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Saving ends in...

Saturday, July 30, 2022 to Thursday, August 25, 2022
Tier 1 - Academics
$1,299
Standard pricing
Saturday, July 30, 2022 to Thursday, August 25, 2022
Tier 2 - Biotech & Pharma
$2,399
Standard pricing
Saturday, July 30, 2022 to Thursday, August 25, 2022
Tier 3 - Industry/Service Provider
$3,699
Standard pricing
Preparing registration...

Venue Description

Venue

Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, United States

For discounted rooms, please click here.

 

RESOURCES

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us